DESTINY PHARMA PLC

AMR Bio Launches with Phase III-Ready Antimicrobial XF-73 to Combat Post-Surgical Infections

- AMR Bio has launched as a clinical-phase biotechnology company to advance XF-73, a first-in-class topical antimicrobial gel designed to prevent post-surgical infections. - The lead product XF-73 Nasal demonstrated a 99.5% reduction in bacterial nasal carriage in a Phase IIb trial of 124 patients undergoing open heart surgery. - Post-surgical infections cost approximately $10 billion annually in the US, while antimicrobial resistance contributes to nearly five million deaths each year globally. - The company has secured regulatory advantages including FDA Fast Track status and UK MHRA Innovation Passport for accelerated market access.